David Alain Wohl, M.D., is an associate professor of medicine in the Division of Infectious Diseases at the University of North Carolina (UNC). He is site leader of the UNC AIDS Clinical Trials Unit at Chapel Hill and codirects HIV services for the North Carolina Department of Correction. In 2011, Dr. Wohl also became director of the North Carolina AIDS Education and Training Center (AETC).
Dr. Wohl's research interests fall into two major areas: the metabolic complications of HIV and its therapies, and the nexus between incarceration and the HIV epidemic. He has chaired several related AIDS Clinical Trials Group (ACTG) studies and receives National Institutes of Health (NIH) funding for his corrections-related research.
Dr. Wohl serves as a member of the Department of Health and Human Services (DHHS) HIV treatment guidelines panel and the NIH Behavioral and Social Consequences of HIV study review section. In addition to his research and administrative activities, Dr. Wohl maintains a large HIV continuity clinic at UNC and sees patients at the North Carolina state prison.
Dr. Wohl has attended advisory boards for Abbott Laboratories, Tibotec and Gilead. In addition, his university received support for his research from GSK Merck.